AM2278
LB892
AJC - 02/01/2024

AMENDMENTS TO LB892

Introduced by Bosn, 25.

1. On page 26, strike line 18 and insert the following new subdivisions:

"(27)(A) Xylazine or any of the substances listed below, including their salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

(i) Xylazine-M (2,6Mich dimethylaniline);

(ii) Xylazine-M (N-thiourea-2,6-dimethylaniline);

(iii) Xylazine-M (sulfone-HO-) isomer 2;

(iv) Xylazine-M (HO-2,6-dimethylaniline isomer 1);

(v) Xylazine-M (HO-2,6-dimethylaniline isomer 2);

(vi) Xylazine M (oxo-);

(vii) Xylazine-M (HO-) isomer 1;

(viii) Xylazine-M (HO-) isomer 1 glucuronide;

(ix) Xylazine-M (HO-) isomer 2;

(x) Xylazine-M (HO-) isomer 2 glucuronide;

(xi) Xylazine-M (HO-oxo-) isomer 1;

(xii) Xylazine-M (HO-oxo-) isomer 1 glucuronide;

(xiii) Xylazine-M (HO-oxo-) isomer 2;

(xiv) Xylazine-M (HO-oxo-) isomer 2 glucuronide;

(xv) Xylazine-M (sulfone); and

(xvi) Xylazine-M (sulfone-HO-) isomer 1.

(B) This subdivision (27) shall not include xylazine when it is used in any of the following manners:

(i) Dispensing or prescribing for, or administering to, a nonhuman species a drug containing xylazine that has been approved by the United States Secretary of Health and Human Services under section 512 of the

AM2278
LB892
AJC - 02/01/2024

Federal Food, Drug, and Cosmetic Act, 21 U.S.C. 360b, as such act existed on January 1, 2024;

(ii) Dispensing or prescribing for, or administering to, a nonhuman species that is permissible under section 512(a)(4) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. 360b(a)(4), as such act existed on January 1, 2024;

(iii) The manufacturing, distribution, or use of xylazine as an active pharmaceutical ingredient for manufacturing an animal drug that has been approved under section 512 of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. 360b, or that has been issued an investigational use exemption under section 512(j) of the act, 21 U.S.C. 360b(j), as such act existed on January 1, 2024;

(iv) The manufacturing, distribution, or use of a xylazine bulk chemical for pharmaceutical compounding by licensed pharmacists or veterinarians for a nonhuman species in accordance with subdivision (B)(i) or (ii) of this subdivision (27); or

(v) Any other use approved or permissible under the Federal Food, Drug, and Cosmetic Act, when dispensed or prescribed for, or administered to, a nonhuman species in accordance with subdivision (B)(i) or (ii) of this subdivision (27).".